Study: No Protection from COVID for People Who Got Pfizer mRNA COVID Shots in 2022-2023
- by Amber Baker
- Published January 23, 2024
- Risk & Failure Reports
Just three years after federal COVID-19 vaccine mandates by the Biden administration forced millions of Americans to choose between their jobs and exercising informed consent rights to protect bodily autonomy, a new study funded by Pfizer found that only the company’s most recent Comirnaty mRNA (messenger ribonucleic acid) COVID shot is effective in preventing symptoms of COVID and that people who received any previous version of Comirnaty had similar outcomes as unvaccinated people.
The paper, which has not been peer reviewed, was published on Dec. 28, 2023 and found no benefit for recipients of past Comirnaty shots.1 2
The updated Comirnaty booster targets the Omicron XBB 1.5 strain of the SARS-CoV-2 virus already on the decline in the United States. While any potential immunity from all vaccines, including mRNA COVID shots wanes over time, Pfizer study researchers determined that previous Comirnaty doses do not protect against hospital admission, emergency room or urgent care visits, or outpatient visits in any meaningful way, but also that certain individuals who received the older Comirnaty doses had a higher risk of hospital admission.2 3
The findings of the study stated:
Older versions of COVID-19 vaccines offered little, if any, additional protection compared to the unvaccinated, including against COVID-19 hospital admission, regardless of the number or type of prior doses received.2
Infectious disease epidemiologist Sara Tartof, PhD, MPH and co-authors of the study wrote:
Compared to the unvaccinated, those who had received only older versions of COVID-19 vaccines did not show significantly reduced risk of COVID-19 outcomes, including hospital admission.2
Higher Risk of Hospital Admission for Those Who Received Two or More Doses of Older Comirnaty Shots
Marketing campaigns for the initial deployment of the experimental Comirnaty shot leaned heavily on the messaging that getting vaccinated would reduce one’s risk of hospitalization from COVID disease, but the latest study does not confirm the accuracy of that message. Dr. Tartof and colleagues found that people who received at least two doses of older Comirnaty shots actually had a “higher risk of outpatient visits and, for some age groups, were more likely to be hospitalized with acute respiratory illness.”2
Some doctors are speculating that Pfizer’s goal in funding the latest study with a negative finding for older Comrinaty shots is to encourage increased uptake of the newest Comirnaty shot, considering that only 14 percent of Americans have gotten a COVID booster shot. Leading Israeli immunologist Ehud Qimron, MD of Tel Aviv University believes conflicts of interest are present, saying the study “reveals a strong bias, potentially influencing the reported results.”2 4
The mRNA COVID shots were not the only public health measure that subsequently proved to be ineffective and even harmful to the public: The conclusions of the Pfizer-funded Comirnaty study revealing the vaccinated had similar outcomes to the unvaccinated come on the heels of former director of the National Institute of Allergy and Infectious Diseases Anthony Fauci, MD testifying in Congress that the six-feet social distancing guidelines had no scientific basis. 5 6
WHO Urges Vaccine Uptake Amid “Incredibly Low” Vaccination Rates
Despite the study finding that previous Comirnaty shots did nothing to prevent COVID disease-associated hospital admissions or emergency room visits in any meaningful way, World Health Organization (WHO) officials continue to urge people to get COVID shots they say will lessen pressure on health care systems dealing with rising hospitalizations for respiratory infections.
“Too many people are in need of serious medical care for flu, for COVID, when we can prevent it,” said Maria Van Kerkhove, PhD, the WHO’s interim director of epidemic and pandemic preparedness, citing “incredibly low” flu and COVID vaccination rates in many countries this season.7
If you would like to receive an e-mail notice of the most recent articles published in The Vaccine Reaction each week, click here.
Click here to view References: